Prediction 1: The Patient-Led Therapy Era Accelerates

Patients are playing a larger role in shaping therapy-related discussions — including interest in advanced therapies such as gene and cell treatments — and are arriving with more defined questions, expectations, and decision scenarios.

Key Signals From 2025

• • Switching and escalation language rose +35% year over year
  • 74% of patients reported strong interest in gene therapy, yet 60% had never discussed it with a clinician
  • When gene therapy discussions do occur, patients or families initiate nearly half — providers initiate only 1 in 10

These behavioral patterns show that patients are taking a more active role in understanding their options and shaping the substance of therapy conversations.

Why This Matters

Brands must be prepared for patients who come to discussions with well-formed expectations, deeper questions, and clearer ideas about therapeutic pathways, making education and expectation-setting increasingly important.

Ways Brands Can Win in 2026

Help patients make sense of real-world therapy pathways — including how decisions typically unfold, what varies, and what questions to bring into the clinical conversation. Doing this well requires trusted environments where patients already explore options and learn from peers.

Prediction 2: AI Handles the Heavy Lift of Rare Disease Interpretation

AI is becoming a common tool for exploration, as reflected in Bionews’ Rare Trust in AI Index. While trust remains low, patients are increasingly using AI to make sense of complex or technical information before turning to trusted, human-created sources to validate what they’ve learned.

Key Signals From 2025

• • Patients reported using AI to interpret labs, compare therapies, research trials, and prepare questions for clinical visits
  • 64% trust AI less than human-created content; only 10% trust it more
  • 40% of respondents had never used AI tools, reflecting the current wide variation in comfort levels with emerging technologies

Many described a consistent pattern: they begin with AI because it is accessible, always available, and allows them to explore questions without judgment — then turn to trusted sources like Bionews to verify or contextualize the information.

These patterns show that AI is influencing how patients explore and make sense of medical information, while trusted environments continue to shape the moments when confidence and decisions form.

Why This Matters

AI is increasingly informing the questions patients ask, but it is not yet where confidence is built. This creates an important opportunity for brands to clarify, contextualize, and support what AI surfaces.

Ways Brands Can Win in 2026

Support patients at the intersection of AI and trust by helping them use AI more effectively — and grounding AI-generated answers in human-verified, condition-specific context that builds confidence.

Prediction 3: Community Becomes the Confidence Engine

Communities have long played an interpretive role in rare disease, and in 2025 that role became even more pronounced as patients used peer experiences to validate expectations, compare pathways, and make sense of uncertainty.

Key Signals From 2025

• • Peer outcome mapping increased 25% year over year, reflecting a growing desire to understand how others experienced similar decisions
  • Trust-gap topics—areas of confusion, conflicting information, or high stakes—generated 27% more replies, indicating that uncertainty drives deeper community engagement
  • Community discussions increasingly centered around real-world decision questions: timing of therapy changes, escalation experiences, expected symptom trajectories, and variation in side effects

These patterns show that community insight is shaping how patients understand what’s possible, what’s typical, and what to expect — especially when navigating complex or evolving treatment landscapes

Why This Matters

As patients face more therapeutic choices and interpret more information outside the clinic, community experiences are becoming a central source of confidence. Patients rely on real-world stories to calibrate expectations, reduce uncertainty, and understand the range of likely outcomes.

Ways Brands Can Win in 2026

Elevate lived experience to help patients understand what’s typical, what’s possible, and what to expect — especially when navigating complex or emerging therapies. Community insight helps reduce uncertainty and build confidence in real decisions.

The Strategic Imperative for 2026

As patients interpret information, compare pathways, and build confidence outside traditional clinical channels, trusted rare disease communities like Bionews have become essential partners.

Across all three trends, a consistent pattern emerges: patients are proactively making sense of complex information, turning to peers to understand real-world experiences, and relying on trusted environments to shape expectations before discussing options with clinicians. Brands that support these moments of understanding and confidence-building will be best positioned to earn trust and deliver meaningful engagement in 2026.

If your team is exploring how to engage rare disease audiences earlier and more effectively, Bionews can help. Connect with us to learn more about partnering on insights, content, and community engagement.